Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

NCT02970942 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatobiliary Disorders
Non-alcoholic Steatohepatitis

Interventions

DRUG: Semaglutide
DRUG: Placebo

Sponsor

Novo Nordisk A/S